WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted...
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing...
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases...
Dosing of the first subject with BB-301 is expected in the second half of 2023, following the rollover of subjects...
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient...
- Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future...
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00 PM EDT at the Lotte...
- Pivotal clinical trial to begin in the third quarter of 2023 - ATLANTA, June 26, 2023 (GLOBE NEWSWIRE) --...
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced...
VALENCIA, Calif., and MELBOURNE, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative...
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants...
POINT’s vertically integrated platform together with AdvanCell’s lead-212 (²¹²Pb) generator technology enables both the development and scaled commercialization of ²¹²Pb-labeled...
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants...
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar...
FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing...
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its...
Integrated eCOA & ePRO Solution Taps Company’s Decentralized Capabilities and Technology ExpertiseMORRISVILLE, N.C., June 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health®...
Avicanna and Medipharm Labs Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian...